181 related articles for article (PubMed ID: 33180025)
1. Advanced Symptom Management System for Patients with Malignant Pleural Mesothelioma (ASyMSmeso): Mixed Methods Study.
Maguire R; Connaghan J; Arber A; Klepacz N; Blyth KG; McPhelim J; Murray P; Rupani H; Chauhan A; Williams P; McNaughton L; Woods K; Moylan A
J Med Internet Res; 2020 Nov; 22(11):e19180. PubMed ID: 33180025
[TBL] [Abstract][Full Text] [Related]
2. A Pilot Mixed-Methods Study of Malignant Pleural Mesothelioma Symptoms.
Walker SL; Vaughan Dickson V; Cacchione PZ
Oncol Nurs Forum; 2022 Oct; 49(6):615-623. PubMed ID: 36413739
[TBL] [Abstract][Full Text] [Related]
3. Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).
Williams LA; Whisenant MS; Mendoza TR; Haq S; Keating KN; Cuffel B; Cleeland CS
Qual Life Res; 2018 Dec; 27(12):3229-3241. PubMed ID: 30187393
[TBL] [Abstract][Full Text] [Related]
4. Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso.
Hollen PJ; Gralla RJ; Liepa AM; Symanowski JT; Rusthoven JJ
Support Care Cancer; 2006 Jan; 14(1):11-21. PubMed ID: 15999264
[TBL] [Abstract][Full Text] [Related]
5. Malignant pleural mesothelioma: treatment patterns and humanistic burden of disease in Europe.
Moore A; Bennett B; Taylor-Stokes G; McDonald L; Daumont MJ
BMC Cancer; 2022 Jun; 22(1):693. PubMed ID: 35739480
[TBL] [Abstract][Full Text] [Related]
6. Content validity and electronic PRO (ePRO) usability of the Lung Cancer Symptom Scale-Mesothelioma (LCSS-Meso) in mesothelioma patients.
Gelhorn HL; Skalicky AM; Balantac Z; Eremenco S; Cimms T; Halling K; Hollen PJ; Gralla RJ; Mahoney MC; Sexton C
Support Care Cancer; 2018 Jul; 26(7):2229-2238. PubMed ID: 29392480
[TBL] [Abstract][Full Text] [Related]
7. Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation.
Hollen PJ; Gralla RJ; Liepa AM; Symanowski JT; Rusthoven JJ
Cancer; 2004 Aug; 101(3):587-95. PubMed ID: 15274072
[TBL] [Abstract][Full Text] [Related]
8. The use of patient-reported outcome measures (PROMs) in the management of malignant pleural mesothelioma: a descriptive literature survey.
Ben Bouazza Y; Van Meerbeeck JP
Transl Lung Cancer Res; 2018 Oct; 7(5):507-515. PubMed ID: 30450288
[TBL] [Abstract][Full Text] [Related]
9. Development of a novel remote patient monitoring system: the advanced symptom management system for radiotherapy to improve the symptom experience of patients with lung cancer receiving radiotherapy.
Maguire R; Ream E; Richardson A; Connaghan J; Johnston B; Kotronoulas G; Pedersen V; McPhelim J; Pattison N; Smith A; Webster L; Taylor A; Kearney N
Cancer Nurs; 2015; 38(2):E37-47. PubMed ID: 24836956
[TBL] [Abstract][Full Text] [Related]
10. Symptom Burden and Unmet Needs in Malignant Pleural Mesothelioma: Exploratory Analyses From the RESPECT-Meso Study.
Hoon SN; Lawrie I; Qi C; Rahman N; Maskell N; Forbes K; Gerry S; Monterosso L; Chauhan A; Brims FJH
J Palliat Care; 2021 Apr; 36(2):113-120. PubMed ID: 32791881
[TBL] [Abstract][Full Text] [Related]
11. Quality of life of survivors of malignant pleural mesothelioma in Japan: a cross sectional study.
Nagamatsu Y; Oze I; Aoe K; Hotta K; Kato K; Nakagawa J; Hara K; Kishimoto T; Fujimoto N
BMC Cancer; 2018 Mar; 18(1):350. PubMed ID: 29587685
[TBL] [Abstract][Full Text] [Related]
12. Usability Evaluation of a Mobile Phone-Based System for Remote Monitoring and Management of Chemotherapy-Related Side Effects in Cancer Patients: Mixed-Methods Study.
Moradian S; Krzyzanowska MK; Maguire R; Morita PP; Kukreti V; Avery J; Liu G; Cafazzo J; Howell D
JMIR Cancer; 2018 Dec; 4(2):e10932. PubMed ID: 30578238
[TBL] [Abstract][Full Text] [Related]
13. A survey of patient and caregiver experience with malignant pleural mesothelioma.
Warby A; Dhillon HM; Kao S; Vardy JL
Support Care Cancer; 2019 Dec; 27(12):4675-4686. PubMed ID: 30944991
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).
Mendoza TR; Williams LA; Keating KN; Siegel J; Elbi C; Nowak AK; Hassan R; Cuffel B; Cleeland CS
J Patient Rep Outcomes; 2019 Jun; 3(1):34. PubMed ID: 31209661
[TBL] [Abstract][Full Text] [Related]
15. Utilizing Digital Health to Collect Electronic Patient-Reported Outcomes in Prostate Cancer: Single-Arm Pilot Trial.
Tran C; Dicker A; Leiby B; Gressen E; Williams N; Jim H
J Med Internet Res; 2020 Mar; 22(3):e12689. PubMed ID: 32209536
[TBL] [Abstract][Full Text] [Related]
16. Communication of a mesothelioma diagnosis: developing recommendations to improve the patient experience.
Taylor BH; Warnock C; Tod A
BMJ Open Respir Res; 2019; 6(1):e000413. PubMed ID: 31179006
[TBL] [Abstract][Full Text] [Related]
17. Feasibility randomised controlled trial of remote symptom chemotherapy toxicity monitoring using the Canadian adapted Advanced Symptom Management System (ASyMS-Can): a study protocol.
Moradian S; Krzyzanowska M; Maguire R; Kukreti V; Amir E; Morita PP; Liu G; Howell D
BMJ Open; 2020 Jun; 10(6):e035648. PubMed ID: 32554724
[TBL] [Abstract][Full Text] [Related]
18. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
[TBL] [Abstract][Full Text] [Related]
19. Tumor-associated macrophage-derived inflammatory cytokine enhances malignant potential of malignant pleural mesothelioma.
Horio D; Minami T; Kitai H; Ishigaki H; Higashiguchi Y; Kondo N; Hirota S; Kitajima K; Nakajima Y; Koda Y; Fujimoto E; Negi Y; Niki M; Kanemura S; Shibata E; Mikami K; Takahashi R; Yokoi T; Kuribayashi K; Kijima T
Cancer Sci; 2020 Aug; 111(8):2895-2906. PubMed ID: 32530527
[TBL] [Abstract][Full Text] [Related]
20. Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.
Stockhammer P; Ploenes T; Theegarten D; Schuler M; Maier S; Aigner C; Hegedus B
Lung Cancer; 2020 Jan; 139():124-132. PubMed ID: 31778960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
